Ferroportin and hepcidin: A new hope in diagnosis, prognosis, and therapy for breast cancer

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERROPORTIN; HEPCIDIN; ANTIMICROBIAL CATIONIC PEPTIDE; CATION TRANSPORT PROTEIN; IRON; METAL TRANSPORTING PROTEIN 1; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; GENE EXPRESSION; PROGNOSIS; BREAST TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM;

ANTIMICROBIAL CATIONIC PEPTIDES; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; FEMALE; HUMANS; IRON; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052912527     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2641     Document Type: Article

References (14)

1. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010, 142:24-38. 10.1016/j.cell.2010.06.028, 20603012.
2. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997, 1331:1-40.
3. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Crit Rev Oncol Hematol 2002, 42:65-78. 10.1016/S1040-8428(01)00213-X, 11923069.
4. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VP, Beland FA, Pogribny IP. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2010,
5. Lieghr JG, Jones JS. Role of iron in estrogen-induced cancer. Curr Med Chem 2001, 8:839-849.
6. Kabat GC, Rohan TE. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 2007, 18:1047-1053. 10.1007/s10552-007-9058-9, 17823849.
7. Huang X. Does iron have a role in breast cancer?. Lancet Oncol 2008, 9:803-807. 2577284, 18672216, 10.1016/S1470-2045(08)70200-6.
8. Jiang XP, Elliot RL, Head JF. Manipulation of iron transported genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res 2010, 30:759-765.
9. Pinnix ZK, Miller LD, Wang W, D'Agostino R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010, 2. 43ra56.
10. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008, 151-158.
11. Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta 2010, 411:1565-1569. 10.1016/j.cca.2010.07.003, 20620132.
12. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent chelators as anti-tumour agents. Biochim Biophys Acta 2009, 1790:702-717.
13. Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, Gilot D, Boudjema K, Guguen-Guillouzo C, Brissot P, Loréal O, Ilyin G. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 2002, 277:41163-41170. 10.1074/jbc.M202653200, 12183449.
14. Sow FB, Alvarez GR, Gross RP, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Role of STAT1, NF-kappaB, and C/EBPbeta in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and IFN-gamma. J Leukoc Biol 2009, 86:1247-1258. 10.1189/jlb.1208719, 19652026.